UY30769A1 - Uso de epotilonas en el tratamiento de la osteoporosis y enfermedades relacionadas - Google Patents

Uso de epotilonas en el tratamiento de la osteoporosis y enfermedades relacionadas

Info

Publication number
UY30769A1
UY30769A1 UY30769A UY30769A UY30769A1 UY 30769 A1 UY30769 A1 UY 30769A1 UY 30769 A UY30769 A UY 30769A UY 30769 A UY30769 A UY 30769A UY 30769 A1 UY30769 A1 UY 30769A1
Authority
UY
Uruguay
Prior art keywords
treatment
osteoporosis
epotilones
related diseases
osteoclastic
Prior art date
Application number
UY30769A
Other languages
English (en)
Inventor
Sanna Kaekinen
Jens Hoffmann
Ulrich Klar
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38008136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY30769(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of UY30769A1 publication Critical patent/UY30769A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso de epotilonas naturales o sintéticas para el tratamiento, la prevencion o la litigacion de enfermedades causadas por el desequilibrio de la actividad osteoclástica y osteoblástica, especialmente la osteoporosis.
UY30769A 2006-12-08 2007-12-07 Uso de epotilonas en el tratamiento de la osteoporosis y enfermedades relacionadas UY30769A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06025424A EP1930004A1 (en) 2006-12-08 2006-12-08 Use of epothilones in the treatment of osteoporosis and related diseases

Publications (1)

Publication Number Publication Date
UY30769A1 true UY30769A1 (es) 2008-07-31

Family

ID=38008136

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30769A UY30769A1 (es) 2006-12-08 2007-12-07 Uso de epotilonas en el tratamiento de la osteoporosis y enfermedades relacionadas

Country Status (15)

Country Link
US (1) US20080146626A1 (es)
EP (2) EP1930004A1 (es)
KR (1) KR20090087038A (es)
CN (1) CN101553227A (es)
AR (1) AR064214A1 (es)
AU (1) AU2007327767A1 (es)
BR (1) BRPI0719997A2 (es)
CA (1) CA2672114A1 (es)
CL (1) CL2007003553A1 (es)
IL (1) IL198493A0 (es)
MX (1) MX2009006074A (es)
TW (1) TW200829239A (es)
UY (1) UY30769A1 (es)
WO (1) WO2008068043A1 (es)
ZA (1) ZA200904755B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105797168A (zh) 2010-05-18 2016-07-27 天蓝制药公司 用于治疗自身免疫性疾病或其它疾病的组合物和方法
RU2496511C1 (ru) * 2012-04-20 2013-10-27 Замертон Холдингс Лимитед Фармацевтическая композиция, средство (варианты) и способ профилактики и лечения артрита, остеоартроза и остеохондроза позвоночника (варианты)
CA3002027A1 (en) 2015-10-16 2017-04-20 William Marsh Rice University Epothilone analogs, methods of synthesis, methods of treatment, and drug conjugates thereof
CN110974824A (zh) * 2019-12-18 2020-04-10 中国人民解放军陆军军医大学第一附属医院 埃博霉素b在制备防治炎症性骨丢失药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6320045B1 (en) * 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
US6893859B2 (en) * 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
WO2002080846A2 (en) * 2001-04-03 2002-10-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
US20060069136A1 (en) * 2004-09-24 2006-03-30 Ulrich Klar Use of Epothilones in the treatment of bone metastasis

Also Published As

Publication number Publication date
MX2009006074A (es) 2009-08-24
BRPI0719997A2 (pt) 2014-03-18
EP1930004A1 (en) 2008-06-11
KR20090087038A (ko) 2009-08-14
IL198493A0 (en) 2010-02-17
CL2007003553A1 (es) 2008-07-04
CA2672114A1 (en) 2008-06-12
CN101553227A (zh) 2009-10-07
AU2007327767A1 (en) 2008-06-12
TW200829239A (en) 2008-07-16
WO2008068043A1 (en) 2008-06-12
AR064214A1 (es) 2009-03-18
ZA200904755B (en) 2010-09-29
EP2101765A1 (en) 2009-09-23
US20080146626A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
CL2009001099A1 (es) Uso de una muteina de interleuquina-2 humana para el tratamiento y/o prevencion de una enfermedad autoinmune.
EA201200550A1 (ru) Фармацевтические композиции, включающие bi-1356 и метформин
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
CR20110100A (es) Nuevos derivados de sulfamida sustituida
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
BRPI0816255A2 (pt) Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
ECSP088745A (es) Derivados sustituidos de cromanol y su uso
AR058173A1 (es) Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas
CL2007003038A1 (es) Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
CL2008002082A1 (es) Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades.
CL2007003672A1 (es) Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad.
UY31133A1 (es) "oxazolidinonas sustituidas y su uso"
CL2007002387A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de artritis y dolor.
DOP2006000280A (es) Nuevos derivados de furopirimidina acíclicos sustituidos y su uso
UY29417A1 (es) Agentes endoparasiticidas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170802